

1. *Standard Chartered PLC, Standard Chartered Holdings Limited, and Standard Chartered Bank*, all of London, United Kingdom; to acquire Harrison Lovegrove & Co. Limited, London, England, and thereby indirectly acquire Harrison Lovegrove Americas L.P., Houston, Texas, and thereby engage in providing advice in connection with mergers, acquisitions, divestitures, investments, joint ventures, leveraged buyouts, recapitalizations, capital structurings, financing transactions and similar transactions, and conducting financial feasibility studies in accordance with Section 225.28(b)(6)(iii); and acting as agent for the private placement of securities, pursuant to Section 225.28(b)(7)(iii), both of Regulation Y.

B. Federal Reserve Bank of Chicago (Burl Thornton, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414:

1. *Capitol Bancorp, Ltd., and Capitol Development Bancorp Limited VIII*, both of Lansing, Michigan; to acquire 51 percent of the voting shares of Community Bank of Lincoln (in organization), Lincoln, Nebraska, and thereby operate a savings association, pursuant to section 225.28(b)(4)(ii) of Regulation Y. Comment on this application must be received by November 5, 2007.

Board of Governors of the Federal Reserve System, October 4, 2007.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. E7-19921 Filed 10-9-07; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL RESERVE SYSTEM

Consumer Advisory Council

ACTION: Notice of Meeting of the Consumer Advisory Council

The Consumer Advisory Council will meet on Thursday, October 25, 2007. The meeting, which will be open to public observation, will take place at the Federal Reserve Board's offices in Washington, DC., in Dining Room E on the Terrace Level of the Martin Building. Anyone planning to attend the meeting should, for security purposes, register no later than Tuesday, October 23, by completing the form found online at: <https://www.federalreserve.gov/secure/forms/cacregistration.cfm>

Additionally, attendees must present photo identification to enter the building.

The meeting will begin at 9 a.m. and is expected to conclude at 1 p.m. The

Martin Building is located on C Street, NW., between 20th and 21st Streets.

The Council's function is to advise the Board on the exercise of the Board's responsibilities under various consumer financial services laws and on other matters on which the Board seeks its advice. Time permitting, the Council will discuss the following topics:

• Home Ownership and Equity Protection Act (HOEPA)

Members will discuss various issues related to the Board's rulemaking authority under HOEPA to address concerns about abusive lending practices in the home mortgage market.

• Regulation Z/Truth in Lending Act (TILA)

Members will discuss issues that have been raised in public comments on the proposed amendments to Regulation Z, which implements the Truth in Lending Act (TILA). The amendments would revise the disclosure requirements for open-end (revolving) plans that are not home-secured, including credit2186d accounts.

Reports by committees and other matters initiated by Council members also may be discussed.

Persons wishing to submit views to the Council on any of the above topics may do so by sending written statements to Jennifer Kerslake, Secretary of the Consumer Advisory Council, Division of Consumer and Community Affairs, Board of Governors of the Federal Reserve System, Washington, D.C. 20551. Information about this meeting may be obtained from Ms. Kerslake, 202-452-6470.

Board of Governors of the Federal Reserve System, October 3, 2007.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. E7-19842 Filed 10-9-07; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 11:30 a.m., Monday, October 15, 2007.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW., Washington, DC 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments,

reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

FOR FURTHER INFORMATION CONTACT:

Michelle Smith, Director, or Dave Skidmore, Assistant to the Board, Office of Board Members at 202-452-2955.

SUPPLEMENTARY INFORMATION: You may call 202-452-3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at <http://www.federalreserve.gov> for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Board of Governors of the Federal Reserve System, October 5, 2007.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 07-5021 Filed 10-5-07; 2:39 pm]

BILLING CODE 6210-01-S

FEDERAL TRADE COMMISSION

Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

Trans #	Acquiring	Acquired	Entities
Transactions Granted Early Termination—09/24/2007			
20072076	UniCredito Italiano S.p.A	Capitalia S.p.A	Capitalia S.p.A.
20072122	Explorer Pipeline Company	Petroleos de Venezuela S.A	Petroleos de Venezuela S.A.
20072129	Abu Dhabi National Energy Company PJSC.	Pioneer Natural Resources Company	Pioneer Natural Resources Canada Inc.
20072145	Great Hill Equity Partners III, L.P	Mark Towfiq and Carol Nakahara	InteleNet Communications, Inc.
20072152	Eugene M. Isenberg	Nabors Industries Ltd	Nabors Industries Ltd.
20072153	Energy Transfer Partners, L.P	MSCP IV CRDI, LLC	Canyon Gas Resources, LLC
20072155	Copano Energy, L.L.C	MSCP IV CRDI, LLC	Cantera Natural Gas, LLC
Transactions Granted Early Termination—09/25/2007			
20072101	Infineon Technologies AG	LSI Corporation	LSI Corporation
20072109	Audax Private Equity Fund II, L.P	Bill D. Brady, as Trustee of the Bill D. Brady Trust.	Brady Holdings, LLC
20072136	S-Process Equipment International S.a.r.l.	Schenck Process SA	Schenck Process Holding GmbH
20072156	AEGON N.V	Merrill Lynch & Co., Inc	Merrill Lynch Life Insurance Company, ML Life Insurance Company of New York
20072160	FleetCor Technologies, Inc	Chevron Corporation	Chevron U.S.A. Inc.
20072163	J.P. Morgan Chase & Co	Sud Chemie AG	Sud Chemie AG
20072165	NTR plc	Edgewater Growth Capital Partners, LP.	Recycled Holdings Corporation
20072167	Babcock & Brown Limited	Bill Sjolander	CMC Industries, Inc., CMC Railroad, Inc.
20072168	Lydian Capital Partners LP	Trilogy Investors, LLC	Trilogy Investors, LLC
20072171	Management Consulting Group PLC	Kurt Salmon Associates, Inc	Kurt Salmon Associates, Inc.
20072185	Thermo Fisher Scientific Inc	Priority Air Holdings Corp	Priority Air Holdings Corp.
Transactions Granted Early Termination—09/26/2007			
20071496	Mylan Laboratories Inc	E. Merck oHG	EMD, Inc., Merck dura GmbH, Merck Genericos S.L., Merck Generics Belgium B.V.B.A., Merck Generics Group B.V.
20072098	RF Micro Devices, Inc	Sirenza Microdevices, Inc	Sirenza Microdevices, Inc.
20072166	Knoll, Inc	Mr. John Edelman	Teddy & Arthur Edelman, Limited
20072172	Industrial Growth Partners III, L.P	Russell W. and Pamela C. Lane	Atlas Material Testing Technology, LLC
20072174	New Mountain Lake Holdings, LLC ..	U.S. Express Enterprises, Inc	U.S. Xpress Enterprises, Inc.
20072188	Gildan Activewear Inc	V.I. Prewett & Son, Inc.	V.I. Prewett & Son, Inc.
Transactions Granted Early Termination—09/27/2007			
20070861	FirstGroup plc	Laidlaw International, Inc	Laidlaw International, Inc.
20071415	Maruha Group Inc	Nichiro Corporation	Nichiro Corporation
Transactions Granted Early Termination—09/28/2007			
20072179	BB&T Corporation	Collateral Holdings, Ltd	Collateral Management, LLC, Collateral Real Estate Capital, LLC
20072184	Carlyle Europe Partners III, L.P	Sociedad General de Aguas de Barcelona, S.A. ("Abgar").	APPLUS Servicios Technologicos, S.L.
20072186	Iconix Brand Group, Inc	Official Pillowtex, LLC	Official Pillowtex, LLC
20072187	Yahoo!, Inc	Zimbra, Inc	Zimbra, Inc.
20072190	American Capital Strategies, Ltd	Wells Fargo & Company	Imperial Supplies LLC
20072195	Warburg Pincus Private Equity IX, L.P.	Integra Telecom, Inc.	Integra Telecom, Inc
20072198	Pfingsten Executive QP Fund III, L.P	Tropitone Furniture Co., Inc	Tropitone Furniture Co., Inc.
20072201	ABRY Partners V, L.P	EHR Holdings, LLC	Executive Health Resources, Inc.
20072204	GSCP Sigma (Lux) S.a.r.l	Sajjan Kumar Agarwal	Gampak Products Corporation, Roemed Holdings, Inc., Semco Electric Private Limited, Sigma Electric Manufacturing Corporation, Ultratech Metals (India) Private Limited
20072205	SECOM Co., LTD	Gordon Crane	Apple & Eve, LLC
20072208	SECOM Co., LTD	Weston Presidio Capital III, LP	Apple & Eve, LLC
20072212	Francois Pinault	United Retail Group, Inc.	United Retail Group, Inc

FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay, Contact Representative or Renee Hallman, Contact Representative.

Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room H-303, Washington, DC 20580, (202) 326-3100.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 07-4969 Filed 10-9-07; 8:45 am]

BILLING CODE 6750-01-M

FEDERAL TRADE COMMISSION

[File No. 071 0164]

**Mylan Laboratories and E. Merck oHG;
Analysis of Agreement Containing
Consent Orders to Aid Public
Comment**

AGENCY: Federal Trade Commission.

ACTION: Proposed Consent Agreement.

SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair or deceptive acts or practices or unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the draft complaint and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before October 27, 2007.

ADDRESSES: Interested parties are invited to submit written comments. Comments should refer to “Mylan/Merck, File No. 071 0164,” to facilitate the organization of comments. A comment filed in paper form should include this reference both in the text and on the envelope, and should be mailed or delivered to the following address: Federal Trade Commission/Office of the Secretary, Room 135-H, 600 Pennsylvania Avenue, NW., Washington, DC 20580. Comments containing confidential material must be filed in paper form, must be clearly labeled “Confidential,” and must comply with Commission Rule 4.9(c). 16 CFR 4.9(c) (2005).¹ The FTC is requesting that any comment filed in paper form be sent by courier or

overnight service, if possible, because U.S. postal mail in the Washington area and at the Commission is subject to delay due to heightened security precautions. Comments that do not contain any nonpublic information may instead be filed in electronic form as part of or as an attachment to email messages directed to the following e-mail box: consentagreement@ftc.gov. The FTC Act and other laws the Commission administers permit the collection of public comments to consider and use in this proceeding as appropriate. All timely and responsive public comments, whether filed in paper or electronic form, will be considered by the Commission, and will be available to the public on the FTC Web site, to the extent practicable, at <http://www.ftc.gov>. As a matter of discretion, the FTC makes every effort to remove home contact information for individuals from the public comments it receives before placing those comments on the FTC Web site. More information, including routine uses permitted by the Privacy Act, may be found in the FTC’s privacy policy, at <http://www.ftc.gov/ftc/privacy.htm>.

FOR FURTHER INFORMATION CONTACT: Kari A. Wallace (202) 326-3085, Bureau of Competition, Room NJ-5108, 600 Pennsylvania Avenue, NW., Washington, DC 20580.

SUPPLEMENTARY INFORMATION: Pursuant to section 6(f) of the Federal Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46(f), and § 2.34 of the Commission Rules of Practice, 16 CFR 2.34, notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC Home Page (for September 27, 2007), on the World Wide Web, at <http://www.ftc.gov/os/2007/09/index.htm>. A paper copy can be obtained from the FTC Public Reference Room, Room 130-H, 600 Pennsylvania Avenue, NW., Washington, DC 20580, either in person or by calling (202) 326-2222.

Public comments are invited, and may be filed with the Commission in either paper or electronic form. All comments should be filed as prescribed in the **ADDRESSES** section above, and must be received on or before the date specified in the **DATES** section.

**Analysis of Agreement Containing
Consent Order to Aid Public Comment**

The Federal Trade Commission (“Commission”) has accepted, subject to final approval, an Agreement Containing Consent Orders (“Consent Agreement”) from Mylan Laboratories (“Mylan”) and E. Merck oHG (“Merck”) which is designed to remedy the anticompetitive effects of the acquisition of certain assets of Merck by Mylan. Under the terms of the proposed Consent Agreement, the companies would be required to assign and divest the Merck rights and assets necessary to manufacture and market generic: (1) Acebutolol hydrochloride capsules; (2) flecainide acetate tablets; (3) guanfacine hydrochloride tablets; (4) nicardipine hydrochloride capsules; and (5) sotalol hydrochloride AF tablets to Amneal Pharmaceuticals LLC (“Amneal”).

The proposed Consent Agreement has been placed on the public record for thirty (30) days for receipt of comments by interested persons. Comments received during this period will become part of the public record. After thirty (30) days, the Commission will again review the proposed Consent Agreement and the comments received, and will decide whether it should withdraw from the proposed Consent Agreement, modify it, or make final the Decision and Order (“Order”).

Pursuant to an Agreement and Plan of Merger executed on May 12 and 13, 2007, Mylan proposes to acquire Merck’s generic subsidiary (“Merck Generics”) and all subsidiaries held directly or indirectly by Merck Generics, by acquiring 100 percent of the issued shares of those subsidiaries for approximately \$6.6 billion. The Commission’s Complaint alleges that the proposed acquisition, if consummated, would violate section 7 of the Clayton Act, as amended, 15 U.S.C. § 18, and section 5 of the Federal Trade Commission Act, as amended, 15 U.S.C. § 45, by lessening competition in the U.S. markets for the manufacture and sale of the following generic pharmaceutical products: (1) Acebutolol hydrochloride capsules; (2) flecainide acetate tablets; (3) guanfacine hydrochloride tablets; (4) nicardipine hydrochloride capsules; and (5) sotalol hydrochloride AF tablets (the “Products”). The proposed Consent Agreement will remedy the alleged violations by replacing the lost competition that would result from the acquisition in each of these markets.

Mylan is a leading developer, manufacturer, marketer, and distributor of generic pharmaceutical drugs. Headquartered in Pennsylvania, Mylan

¹ The comment must be accompanied by an explicit request for confidential treatment, including the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. The request will be granted or denied by the Commission’s General Counsel, consistent with applicable law and the public interest. See Commission Rule 4.9(c), 16 CFR 4.9(c).